PREDICTING RESPONSE TO EPIGENETIC DRUG THERAPY

摘要

The present invention relates to the field of epigenetics. More specifically, the present invention provides methods and compositions useful for predicting response to epigenetic drug therapy. As described herein, we have identified a unique signature termed AZA Immune gene set or AIM that differentiates patients with a low immune and high immune signature and is regulated by epigenetic drugs such as demethylating drugs, histone deacetylase inhibitors. In certain embodiments, patients with a high immune signature may benefit from immunotherapies such as anti PD1 or anti PDL1 antibodies or vaccines. In other embodiments, patients with a low immune signature or low AIM would be patients who would then benefit from treatment with epigenetic drugs and then subsequent immunotherapy.

主权项

1. A method for treating a patient having cancer comprising the steps of:
a. obtaining a biological sample from the patient; b. generating gene expression data from the biological sample; c. classifying the gene expression data from the biological sample as high or low AIM based on a comparison to an AIM panel described herein; and d. treating the cancer patient with immunotherapy if the gene expression data from the biological sample is classified as high AIM or treating the cancer patient with epigenetic therapy followed by immunotherapy if the gene expression data from the biological sample is classified as low AIM.